Eli Lilly (LLY) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1,251.61, +3.55% vs the prior close of $1,208.74.
- Volume 3.75M shares, 1.5x its 50-day average.
- New SEC filings: 144 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
LLY jumps 3.5% to $1,251.61, a 1-month high. Closed at $1,251.61, +3.55% vs the prior close of $1,208.74. Day range $1,230.66–$1,275.88, opened at $1,235.04.
LLY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — LLY jumps 3.5% to $1,251.61, a 1-month high
- Closed at $1,251.61, +3.55% vs the prior close of $1,208.74. Day range $1,230.66–$1,275.88, opened at $1,235.04.
- Volume was 3.75M shares, 1.5x its 50-day average of 2.46M.
- Price is +6.2% vs its 50-day average ($1,179.04) and +16.0% vs its 200-day average ($1,079.02).
- 52-week range $783.85–$1,292.65; today's close sits at 92% of that range, 3.2% below the 52-week high.
Oct 14, 2026 — LLY jumps 3.6% to $1,208.74, a 1-month high
- Closed at $1,208.74, +3.62% vs the prior close of $1,166.51. Day range $1,174.24–$1,216.71, opened at $1,177.87.
- Volume was 3.16M shares, 1.3x its 50-day average of 2.48M.
- Price is +2.7% vs its 50-day average ($1,177.41) and +12.1% vs its 200-day average ($1,078.16).
- 52-week range $783.85–$1,292.65; today's close sits at 84% of that range, 6.5% below the 52-week high.
Oct 13, 2026 — LLY dips 1.4% to $1,166.51
- Closed at $1,166.51, -1.36% vs the prior close of $1,182.62. Day range $1,158.41–$1,193.30, opened at $1,190.70.
- Volume was 1.84M shares, 0.7x its 50-day average of 2.50M.
- Price is -0.8% vs its 50-day average ($1,175.55) and +8.3% vs its 200-day average ($1,077.50).
- 52-week range $783.85–$1,292.65; today's close sits at 75% of that range, 9.8% below the 52-week high.
Oct 12, 2026 — LLY ends flat (+0.3%) to $1,182.62
- Closed at $1,182.62, +0.28% vs the prior close of $1,179.27. Day range $1,172.81–$1,188.70, opened at $1,181.24.
- Volume was 1.25M shares, 0.5x its 50-day average of 2.53M — lighter than usual.
- Price is +0.7% vs its 50-day average ($1,174.64) and +9.8% vs its 200-day average ($1,077.06).
- 52-week range $783.85–$1,292.65; today's close sits at 78% of that range, 8.5% below the 52-week high.
Oct 9, 2026 — LLY rises 0.8% to $1,179.27
- Closed at $1,179.27, +0.83% vs the prior close of $1,169.60. Day range $1,151.67–$1,179.82, opened at $1,153.56.
- Volume was 1.39M shares, 0.5x its 50-day average of 2.56M — lighter than usual.
- Price is +0.5% vs its 50-day average ($1,173.97) and +9.5% vs its 200-day average ($1,076.50).
- 52-week range $783.85–$1,292.65; today's close sits at 78% of that range, 8.8% below the 52-week high.
Oct 8, 2026 — LLY dips 1.6% to $1,169.60
- Closed at $1,169.60, -1.61% vs the prior close of $1,188.72. Day range $1,131.21–$1,186.09, opened at $1,183.50.
- Volume was 3.09M shares, 1.2x its 50-day average of 2.54M.
- Price is -0.3% vs its 50-day average ($1,173.48) and +8.7% vs its 200-day average ($1,075.99).
- 52-week range $783.85–$1,292.65; today's close sits at 76% of that range, 9.5% below the 52-week high.
Oct 7, 2026 — LLY rises 2.7% to $1,188.72, a 1-month high, 3 up days in a row
- Closed at $1,188.72, +2.70% vs the prior close of $1,157.49. Day range $1,166.00–$1,206.63, opened at $1,173.62.
- Volume was 2.30M shares, 0.9x its 50-day average of 2.55M.
- Price is +1.2% vs its 50-day average ($1,174.29) and +10.5% vs its 200-day average ($1,075.50).
- 52-week range $783.85–$1,292.65; today's close sits at 80% of that range, 8.0% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — LLY rises 1.3% to $1,157.49
- Closed at $1,157.49, +1.26% vs the prior close of $1,143.12. Day range $1,139.98–$1,177.07, opened at $1,147.15.
- Volume was 2.13M shares, 0.8x its 50-day average of 2.53M.
- Price is -1.5% vs its 50-day average ($1,174.93) and +7.7% vs its 200-day average ($1,074.84).
- 52-week range $783.85–$1,292.65; today's close sits at 73% of that range, 10.5% below the 52-week high.
Oct 5, 2026 — LLY ends flat (+0.0%) to $1,143.12
- Closed at $1,143.12, +0.02% vs the prior close of $1,142.85. Day range $1,139.50–$1,165.73, opened at $1,150.76.
- Volume was 1.98M shares, 0.8x its 50-day average of 2.53M.
- Price is -2.8% vs its 50-day average ($1,175.73) and +6.4% vs its 200-day average ($1,074.26).
- 52-week range $783.85–$1,292.65; today's close sits at 71% of that range, 11.6% below the 52-week high.
Oct 2, 2026 — LLY dips 0.6% to $1,142.85, 4 down days in a row
- Closed at $1,142.85, -0.61% vs the prior close of $1,149.85. Day range $1,136.66–$1,164.92, opened at $1,153.82.
- Volume was 2.05M shares, 0.8x its 50-day average of 2.53M.
- Price is -2.9% vs its 50-day average ($1,176.79) and +6.4% vs its 200-day average ($1,073.81).
- 52-week range $783.85–$1,292.65; today's close sits at 71% of that range, 11.6% below the 52-week high.
- That makes 4 straight losses.
LLY latest news & SEC filings
Every SEC filing by or about LLY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 8, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 7, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 22, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sulzberger Gabrielle received an award of 4 shares at $1,164.89 (≈$4.96K) on Sep 21, 2026; now holds 3,012
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Luciano Juan R received an award of 14 shares at $1,164.89 (≈$15.92K) on Sep 21, 2026; now holds 16,957
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Fyrwald J Erik received an award of 9 shares at $1,164.89 (≈$9.92K) on Sep 21, 2026; now holds 75,536
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 5, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $22.97B (prior year $15.56B) (+47.7% vs Jun 30, 2025)
- Net income: $7.09B (prior year $5.66B) (+25.3% vs Jun 30, 2025)
- Diluted EPS: $7.94 (prior year $6.29) (+26.2% vs Jun 30, 2025)
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 24, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 24, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 23, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 23, 2026 · 11-K — Annual report for an employee stock plan
Annual report for an employee stock plan
Things to know before you trade LLY
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 4, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.24% (largest 3.6%).
- Liquidity: about 2.41M shares (≈$3.01B) trade per day on average.
- 52-week position: $1,251.61 vs a range of $783.85–$1,292.65 (92% of the range).
- Dividends: last ex-dividend date Aug 14, 2026 ($1.73/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Patrik Jonsson sold 6,500 shares on Aug 17, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K May 20, 2026.
- Share count: 941.36M shares outstanding (Aug 3, 2026), -0.5% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
LLY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1,235.04 | 1,275.88 | 1,230.66 | 1,251.61 | 3.75M |
| Oct 14, 2026 | 1,177.87 | 1,216.71 | 1,174.24 | 1,208.74 | 3.16M |
| Oct 13, 2026 | 1,190.70 | 1,193.30 | 1,158.41 | 1,166.51 | 1.84M |
| Oct 12, 2026 | 1,181.24 | 1,188.70 | 1,172.81 | 1,182.62 | 1.25M |
| Oct 9, 2026 | 1,153.56 | 1,179.82 | 1,151.67 | 1,179.27 | 1.39M |
| Oct 8, 2026 | 1,183.50 | 1,186.09 | 1,131.21 | 1,169.60 | 3.09M |
| Oct 7, 2026 | 1,173.62 | 1,206.63 | 1,166.00 | 1,188.72 | 2.30M |
| Oct 6, 2026 | 1,147.15 | 1,177.07 | 1,139.98 | 1,157.49 | 2.13M |
| Oct 5, 2026 | 1,150.76 | 1,165.73 | 1,139.50 | 1,143.12 | 1.98M |
| Oct 2, 2026 | 1,153.82 | 1,164.92 | 1,136.66 | 1,142.85 | 2.05M |
| Oct 1, 2026 | 1,155.00 | 1,158.72 | 1,139.85 | 1,149.85 | 2.17M |
| Sep 30, 2026 | 1,186.49 | 1,215.00 | 1,155.27 | 1,157.08 | 3.41M |
| Sep 29, 2026 | 1,186.05 | 1,192.94 | 1,168.47 | 1,184.63 | 1.66M |
| Sep 28, 2026 | 1,180.30 | 1,194.09 | 1,172.56 | 1,184.78 | 1.97M |
| Sep 25, 2026 | 1,185.32 | 1,190.00 | 1,160.84 | 1,183.46 | 1.92M |
| Sep 24, 2026 | 1,156.67 | 1,197.79 | 1,151.00 | 1,181.89 | 2.42M |
| Sep 23, 2026 | 1,174.71 | 1,188.88 | 1,145.98 | 1,150.99 | 2.15M |
| Sep 22, 2026 | 1,146.15 | 1,180.53 | 1,139.26 | 1,170.14 | 2.45M |
| Sep 21, 2026 | 1,144.50 | 1,170.90 | 1,134.41 | 1,164.89 | 2.48M |
| Sep 18, 2026 | 1,150.00 | 1,157.60 | 1,140.27 | 1,152.93 | 4.54M |
About Eli Lilly
Eli Lilly (LLY) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in INDIANAPOLIS, IN. State of incorporation: IN. Fiscal year ends December 31. SEC CIK 59478.
LLY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ralph Alvarez | Director | Sep 22, 2026 |
| Katherine Baicker | Director | Nov 18, 2025 |
| Carolyn R Bertozzi | Director | Dec 8, 2025 |
| J Erik Fyrwald | Director | Sep 22, 2026 |
| Mary Lynne Hedley | Director | Dec 16, 2025 |
| Jamere Jackson | Director | Nov 18, 2025 |
| Kimberly H Johnson | Director | Nov 18, 2025 |
| William G Jr Kaelin | Director | Nov 18, 2025 |
| Juan R Luciano | Director | Sep 22, 2026 |
| Jon R Moeller | Director | Nov 18, 2025 |
| David A Ricks | President, Chair, and CEO | Feb 11, 2026 |
| Gabrielle Sulzberger | Director | Sep 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Adrienne S Brown | EVP, President LLY Imm | Sep 4, 2026 |
| Kenneth L. Custer | EVP & President, Card Met Hlth | Feb 18, 2026 |
| Eric Dozier | EVP, Chief People Officer | Sep 4, 2026 |
| Anat Hakim | EVP, GC & Secretary | Aug 10, 2026 |
| Edgardo Hernandez | EVP & Pres., Mfg. Operations | Sep 4, 2026 |
| Carole Ho | EVP & Pres, Lilly Neuroscience | Jan 6, 2026 |
| Patrik Jonsson | EVP & President, LLY Int'l | Aug 18, 2026 |
| Lucas Montarce | EVP & CFO | Feb 18, 2026 |
| Diogo Rau | EVP & CIDO | Feb 12, 2026 |
| David A Ricks | President, Chair, and CEO | Feb 11, 2026 |
| Melissa Seymour | EVP, Global Quality | Sep 11, 2026 |
| Daniel Skovronsky | EVP, CS&PO & Pres. LRL | Feb 11, 2026 |
| Naarden Jacob Van | EVP,Pres LLY Oncology&HdCorpBD | Feb 11, 2026 |
| Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | Jun 11, 2026 |
| Donald A Zakrowski | SVP, Finance, & CAO | Aug 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Patrik Jonsson | Sale | 6,500 | $1,175.10 |
| Aug 10, 2026 | Donald A Zakrowski | Sale | 2,000 | $1,185.01 |
| Aug 7, 2026 | Anat Hakim | Sale | 5,000 | $1,190.00 |
| Jun 10, 2026 | Ilya Yuffa | Sale | 2,500 | $1,150.77 |
| May 6, 2026 | Endowment Inc Lilly | Sale | 2,208 | $996.18 |
| May 6, 2026 | Endowment Inc Lilly | Sale | 13,620 | $995.23 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 930 | $1,088.97 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 3,575 | $1,090.18 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 1,224 | $1,091.05 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 1,072 | $1,092.56 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 1,322 | $1,093.58 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 420 | $1,094.70 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 475 | $1,095.74 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 6,408 | $1,097.41 |
| Jan 7, 2026 | Endowment Inc Lilly | Sale | 9,573 | $1,098.55 |
LLY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $65.18B | $20.64B | 22.95 | $16.81B |
| Dec 31, 2024 | $45.04B | $10.59B | 11.71 | $8.82B |
| Dec 31, 2023 | $34.12B | $5.24B | 5.80 | $4.24B |
| Dec 31, 2022 | $28.54B | $6.24B | 6.90 | $7.59B |
| Dec 31, 2021 | $28.32B | $5.58B | 6.12 | $7.37B |
Latest balance sheet: total assets $142.28B, total liabilities $—, cash $8.95B (as of Jun 30, 2026).
LLY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $1,169.86 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $934.60 |
| Feb 4, 2026 | 8-K Item 2.02 (results) | $1,107.12 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $844.50 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $640.86 |
| May 1, 2025 | 8-K Item 2.02 (results) | $794.10 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $870.37 |
| Jan 14, 2025 | 8-K Item 2.02 (results) | $744.91 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $846.83 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| Apr 30, 2024 | 8-K Item 2.02 (results) | — |
| Feb 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on LLY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.